Product
Endocrine therapy combined with the local treatment of FES-negative lesions
1 clinical trial
1 indication
Indication
Breast CancerClinical trial
ECLECTIC: EstroTEP and Circulating Biomarkers to Determine the Optimal Second Line Therapy for ER-positive HER2-negative Metastatic Breast Cancer PatientsStatus: Recruiting, Estimated PCD: 2028-08-15